StockData

InnovAge vs Pennant

INNV and PNTG side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INNV and PNTG compare

InnovAge and Pennant are about the same size, with market caps of $1.3B and $1.3B.

Pennant grew revenue faster over the last twelve months (37.9% versus 15.9% for InnovAge).

Pennant keeps more of each dollar of sales as profit, with a net margin of 2.9% compared with −0.26% at InnovAge.

Pennant scores higher on the StockData Score (13 against 11 for InnovAge), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINNVPNTG
Size and price
Market cap$1.3B$1.3B
Share price$9.42$36.50
Change, 1 year94.6%46.6%
Change, 5 years23.8%78.5%
Beta (5Y)−0.150.64
Employees2,5009,700
StockData Score
Total score1113 (better)
Valuation score03 (better)
Growth score34 (better)
Performance score33
Health score5 (better)3
Dividend score00
Valuation
P/E–40.6×
P/S1.3×1.2× (better)
P/B5.5×–
EV/EBITDA50.3×18.1× (better)
P/FCF25.5× (better)36.8×
PEG–0.72
FCF yield3.9% (better)2.7%
Fair value$5.76$29.76
Margin of safety−63.5%−22.7% (better)
Growth
Revenue growth (TTM)15.9%37.9% (better)
Revenue growth, 5Y average9.2%19.4% (better)
Net income growth (TTM)–20.5%
EPS growth (TTM)–15.4%
EPS growth, 5Y average–10.1%
Profitability
Gross margin23.0% (better)18.5%
Operating margin0.26%5.6% (better)
Net margin−0.26%2.9% (better)
FCF margin5.1% (better)3.1%
Return on equity−1.1%–
Return on invested capital1.2%–
Financial health
Debt / equity0.20–
Net debt / EBITDA−3.93−0.14
Interest coverage–5.8×
Current ratio1.051.20 (better)
Altman Z-score4.22 (better)2.65
Piotroski F-score6 (better)5
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions13.5%92.7%
Held by insiders75.4%5.0%
Insider net buying, 12 months−$227M−$690K (better)
Short interest, % of float2.7%3.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.